---
trial_id: 820
discovery_date: 2022-05-15 20:21:08.586041
date: 2022-05-15 20:21:08.586041
title: "A two-year, double-blind, randomized, multicenter, active controlled
study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon Î²-1a i.m. once weekly ..."
summary: |
  <p>EudraCT Number: 2011-005677-23<br />Sponsor Protocol Number: CFTY720D2311<br />Sponsor Name: Novartis Farma<br />Start Date: 2013-04-02<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 15.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/DE">DE</a> (Restarted), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/RO">RO</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/EE">EE</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/HR">HR</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005677-23'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2011-005677-23<br />Sponsor Protocol Number: CFTY720D2311<br />Sponsor Name: Novartis Farma<br />Start Date: 2013-04-02<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 15.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/DE">DE</a> (Restarted), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/RO">RO</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/EE">EE</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/HR">HR</a> (Completed)</p>